

3Q2021 EARNINGS PRESENTATION

NOVEMBER 8, 2021



Cautionary Note Regarding Forward Looking Statements

Certain statements included in this presentation may be considered forward-looking. All statements in this presentation that are not historical facts are forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be taken as guarantees of future performance or results. We may use words such as "expects," "anticipates," "intends," "plans," "believes," "could," "seeks," "estimates," and variations of such words and similar expressions in identifying forward-looking statements. The forward-looking statements herein include, but not limited to, statements concerning: our possible or assumed future results of operations; our business strategies; our ability to attract and retain customers; our ability to sell additional products and services to customers; our cash needs and financing plans; our competitive position; our industry environment; our potential growth opportunities; expected technological advances by us or by third parties and our ability to leverage them; the effects of future regulation; and the effects of competition. These statements are based on our management's beliefs and assumptions and on information currently available to our management. It is important to note that forward-looking statements are not guarantees of future performance, and that our actual results could differ materially from those set forth in any forward-looking statements. Due to risks and uncertainties, actual events may differ materially from current expectations. For a more in-depth discussion of these and other factors that could cause actual results to differ from those contained in forward-looking statements, see the discussions under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K and other documents that the Company has subsequently filed with the SEC. Vuzix disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.



Call Participants and Agenda

Participants

Paul Travers

President and CEO

Grant Russell

CFO and Executive Vice President

Ed McGregor

Director of Investor Relations

<u>Agenda</u>

- > Introduction
- > 3Q2021 business review
- ➤ 3Q2021 financial review
- > Q&A
- Closing remarks



Opening Remarks


- 3Q Smart Glasses revenue grew sequentially and YOY
- Expansion of distributor network across multiple regions
- Demand remains strong in the healthcare business segment




- Increased visibility toward large deployments in warehousing, logistics and training
- Pipeline of OEM opportunities continues to expand
- > Ended 3Q with ~\$129M in cash




Vuzix' Smart Glasses Revenue Continues to Grow







The Metaverse Will Be a Significant Positive for Vuzix and the Industry



Key Verticals: Logistics Is Emerging and Healthcare is Accelerating

- Seeing smart glasses demand growth across all major geographies
- ➤ Within logistics, retail stores, distribution centers, 3rd party logistics, warehousing and inventory management customers are focused on deploying smart glasses
- Within healthcare, smart glasses use for patient care, medical training and education and surgery are all gaining traction





Ohana One

Ohana One International Surgical Aid and Education Launches Virtual Surgical Sight Smart Glasses Program with Vuzix

The Ohana One
Surgical Sight Smart
Glass program
continues to expand



1Q2021

2Q2021

3Q2021

4Q2021



Ohana One International
Virtual Surgical Sight
Program Utilizing Vuzix
Smart Glasses Now Live in
35 Countries Worldwide





Medacta

Hospital for Special Surgery utilizes
Augmented Reality platform and
Vuzix Blade Smart Glasses for knee
replacement surgery

Vuzix Blade Smart Glasses Successfully
Supporting Medacta's NextAR Surgical
Platform - Volume follow-on orders for
Vuzix Blades received as a proven
hardware solution of choice

Completion of the first shoulder surgeries with NextAR Shoulder technology in France



1Q2021

2Q2021

3Q2021

4Q2021


Medacta Announces the Registration of the Knee,
Shoulder and Spine Applications of its NextAR
Augmented Reality Surgical Platform in Europe, and the
Shoulder Application to the American Market

Medacta Announces Successful Completion of First Reverse Shoulder Arthroplasties using NextAR Augmented Reality Surgical Platform



In Parma, Italy, the first shoulder prosthetic surgery with augmented reality







Vuzix Expands its Global Smart
Surgeries Presence by Collaborating
with Rods & Cones for M-Series
Smart Glasses Platform Support

Vuzix Receives New
Orders for Over \$1.2
million of Smart Glasses
from Rods & Cones to
Support Virtual Surgical
Collaboration Rollout

A mitral valve surgery proctoring session, set up with the usage of our remote access service to the OR, was led by Prof. Dr. Med Jörg Kempfert in the Deutsches Herzzentrum Berlin (DHZB) to the team of Dr Marco Solinas in Massa Carrara.



1Q2021

2Q2021

3Q2021

4Q2021

Vuzix Receives Initial Smart Glasses

Deployment Order from Healthcare
and Surgical Training Provider



Gynaecologists Dr. Martine
Wassen and Dr. Nicol Smeets were the
first in the Netherlands to perform
vNOTES at the Zuyderland Hospital; this
state-of-the-art technique is now being
taught to residents, who reported to have
a more complete view of the theatre than
as if they would be in the operating room.

Full robotic esophagectomy live streamed from University Medical Center Utrecht for advanced course by Bernard Dallemagne Silvana Perretta.





Medtronic

Medtronic UK & Ireland

Mr Neil Davidson, Alder Hey Hospital, is the first UK spinal surgeon to utilize the cutting edge Vuzix smart glasses with Medtronic for remote support of a live clinical spinal procedure



Prof Ganesh Manoharan and Dr Saber Hassan on the first remote proctored case in the UK & Ireland today at the Mater Private Network Hospital in Dublin.



1Q2021 2Q2021 3Q2021 4Q2021



Medtronic Netherlands




MedtronicUK enabling collaborative surgery along side technology and procedure proctorship and peer to peer teaching at both under- and post-grad level at Matersurgery



Vascular surgeons Robin Hulsebos and Joost Bekken at Noordwest Ziekenhuisgroep hospital in Netherlands were the first vascular surgeons worldwide to have X-ray screening images viewed remotely. This innovative technology is currently being tested within Medtronic in collaboration with several hospitals to provide remote support and training and education purposes



3 Segments Will Drive Vuzix' Long-Term Growth and Profitability



^{*} Segment sizes are not to expected scale



Ongoing Hardware and Software Developments

- Vuzix remains on track to deliver NGSG DTV units this year
- Vuzix expects to introduce three new monocular line extensions to its smart glasses family in 2022
- Vuzix is evaluating multiple SaaS-based opportunities and due diligence is progressing well
- Vuzix' Custom Solutions group is already engaged with a number of organizations





Leverage, Expand and Monetize Core Technologies



- 233 patents and patents pending
- Control and ownership of key technologies will significantly enhance shareholder value
- Continuing due diligence on the acquisition of a disruptive nano electrooptical technology



3Q2021 Operating Results

		3Q2021	3Q2020	% Change
Revenue:	Smart Glasses Eng. Services Total	\$3.02M - \$3.02M	\$2.69M \$0.09M \$2.78M	+9% - +9%
Gross Profit		\$0.58M	\$0.35M	+68%
Gross Margin		19.3%	12.5%	+54%
Total Expenses		\$8.41M	\$5.10M	+65%
Operating (Loss)		\$(7.83)M	\$(4.75)M	-65%
EPS (Loss)		\$(0.13)	\$(0.13)	0%



Balance Sheet Highlights

	9/30/2021	6/30/2021	12/31/2020
Cash	\$128.7M	\$137.6M	\$36.1M
Current Assets	\$144.0M	\$151.0M	\$45.1M
Working Capital	\$140.5M	\$147.9M	\$42.0M
Long-Term Debt	0	0	0
Preferred Stock	0	0	4.96M shares*
Shareholder Equity	\$151.3M	\$155.7M	\$48.3M



^{*} Preferred conversion shares

Q&A